Treace Medical Concepts, Inc. Stock
Equities
TMCI
US89455T1097
Medical Equipment, Supplies & Distribution
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
7.920 USD | -0.13% | -9.79% | -37.88% |
Capitalization | 493M 466M 433M 386M 697M 41.87B 763M 5.38B 1.99B 17.18B 1.85B 1.81B 74.52B | P/E ratio 2024 * |
-8.56x | P/E ratio 2025 * | -10.5x |
---|---|---|---|---|---|
Enterprise value | 456M 431M 400M 357M 644M 38.69B 705M 4.97B 1.83B 15.88B 1.71B 1.67B 68.87B | EV / Sales 2024 * |
2.2x | EV / Sales 2025 * | 2.09x |
Free-Float |
-
| Yield 2024 * |
-
| Yield 2025 * | - |
Last Transcript: Treace Medical Concepts, Inc.
1 day | -0.13% | ||
1 week | -9.79% | ||
Current month | -7.04% | ||
1 month | -1.49% | ||
3 months | +52.60% | ||
6 months | +34.01% | ||
Current year | -37.88% |
Director | Title | Age | Since |
---|---|---|---|
John Treace
CEO | Chief Executive Officer | 52 | 2013-12-31 |
Mark Hair
DFI | Director of Finance/CFO | 54 | 2020-08-31 |
Terry Lubben
COO | Chief Operating Officer | - | - |
Manager | Title | Age | Since |
---|---|---|---|
John Treace
BRD | Director/Board Member | 52 | 2013-12-31 |
James Treace
CHM | Chairman | 77 | 2014-06-30 |
Richard Mott
BRD | Director/Board Member | 65 | 2015-02-28 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.00% | 9 M€ | -.--% | - |
Change | 5d. change | 1-year change | 3-years change | Capi. ($) | ||
---|---|---|---|---|---|---|
-0.13% | -9.79% | -16.63% | -54.61% | 494M | ||
-0.01% | +0.01% | +92.19% | +84.13% | 12.57B | ||
+1.53% | -1.63% | +7.51% | -3.57% | 9.1B | ||
-0.16% | -1.26% | +62.44% | -38.75% | 9.09B | ||
-2.99% | +2.62% | +41.29% | +72.98% | 5.12B | ||
+0.10% | -1.13% | -5.74% | +4.29% | 4.78B | ||
-1.30% | -2.51% | +0.21% | -3.63% | 4.67B | ||
+1.55% | +1.05% | -25.04% | -55.40% | 4.27B | ||
+2.47% | -4.02% | +129.20% | -67.36% | 3.03B | ||
+4.52% | +2.44% | -15.32% | -33.29% | 2.99B | ||
Average | +0.56% | -1.42% | +27.01% | -9.52% | 5.61B | |
Weighted average by Cap. | +0.34% | -0.64% | +39.37% | +8.60% |
2024 * | 2025 * | |
---|---|---|
Net sales | 208M 196M 182M 162M 293M 17.61B 321M 2.26B 835M 7.23B 779M 762M 31.34B | 225M 213M 197M 176M 318M 19.09B 348M 2.45B 906M 7.83B 845M 827M 33.98B |
Net income | -57.09M -53.96M -50.06M -44.64M -80.63M -4.84B -88.33M -622M -230M -1.99B -214M -210M -8.62B | -47.73M -45.11M -41.85M -37.32M -67.4M -4.05B -73.84M -520M -192M -1.66B -179M -175M -7.21B |
Net Debt | -37.42M -35.37M -32.81M -29.26M -52.84M -3.18B -57.89M -408M -151M -1.3B -141M -137M -5.65B | -24.09M -22.77M -21.13M -18.84M -34.02M -2.04B -37.28M -263M -96.95M -839M -90.47M -88.5M -3.64B |
Date | Price | Change | Volume |
---|---|---|---|
24-12-09 | 7.920 $ | -0.13% | 170,258 |
24-12-06 | 7.930 $ | +2.32% | 201,870 |
24-12-05 | 7.750 $ | -3.85% | 295,916 |
24-12-04 | 8.060 $ | -5.73% | 453,498 |
24-12-03 | 8.550 $ | -2.62% | 354,547 |
Delayed Quote Nasdaq, December 09, 2024 at 04:00 pm EST
More quotesQuarterly revenue - Rate of surprise
- Stock Market
- Equities
- TMCI Stock